Here’s What Analysts Think About Halozyme Therapeutics (HALO)

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the best affordable stocks with good earnings growth for 2026. Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced on December 18 that Johnson & Johnson received approval from the U.S. Food and Drug Administration (FDA) for RYBREVANT FASPRO, co-formulated with ENHANZE® for people with epidermal growth factor receptor (EGFR)-mutated locally advanced or metastatic non-small cell lung cancer. RYBREVANT FASPRO holds approval across all indications of RYBREVANT, and marks the first and only subcutaneously administered targeted therapy for patients with EGFR+ mNSCLC.

Is Halozyme Therapeutics, Inc. (HALO) the Unstoppable Growth Stock to Invest in Now?

Management further reported that RYBREVANT FASPRO delivered a significant reduction in administration time from several hours to around five minutes when compared to intravenous delivery, and exhibited an approximately fivefold reduction in administration-related reactions; 13% in subcutaneous compared to 66% in intravenous arm. Dr. Helen Torley, president and chief executive officer of Halozyme Therapeutics, Inc. (NASDAQ:HALO), stated that RYBREVANT FASPRO holds the potential to make administration more convenient and faster for patients due to the company’s leading ENHANZE drug delivery technology.

In a separate development, Halozyme Therapeutics, Inc. (NASDAQ:HALO) received a rating update from TD Cowen on December 5, who reaffirmed a Buy rating on the stock with a $79 price target. However, Halozyme Therapeutics, Inc. (NASDAQ:HALO) was downgraded to Sell from Neutral by Goldman Sachs on December 4, with the firm setting a $56 price target. The firm told investors that a central debate for the company is the long-term value of its Enhanze royalty model, which faces a considerable post-2030 revenue cliff with around 70% of the royalties rolling off on the contract between 2030 and 2035. Typical business-development pacing appears inadequate to offset this trend, according to the firm.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a biopharmaceutical technology platform company that develops, manufactures, and commercializes drug-device combination products through advanced auto-injector technology. They offer commercial or functional benefits, including increased patient comfort and adherence, and enhanced tolerability and convenience.

While we acknowledge the potential of HALO to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than HALO and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.